Emergent BioSolutions Inc.: stock overview

EBSNYSEHealthcare · Pharmaceutical Preparations

Price

$5.79

November 13, 2026Market cap $300M

DCF calculator

What Ploutos Investor adds for Emergent BioSolutions

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Emergent BioSolutions had revenue of $649M over the last 12 months and a net loss of $261M. Revenue fell by 13.7% a year on average over the last 5 years. It has net debt of $332M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$300M
51.77M shares
P/E
–
Revenue, 12 months
$649M
-13.7% a year over 5 years
Net margin
-40.2%
2025: 7.1%, above 70% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-15.9% a year over 2 years

  • 202510-K
    Revenue$743M
  • 202410-K
    Revenue$1.0B
  • 202310-K
    Revenue$1.0B

Fiscal years in figures

EBS's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $519M
$300M
Enterprise value 
$632M
P/E 
–
EV / EBIT 
–
EV / Revenue 
1.0
P/B 3-year median: 1.1
1.0
FCF yield 3-year median: 6.9%
62.8%
Earnings yield 3-year median: -37.7%
–

Profitability

Gross margin 
48.4%
Operating margin 
-27.7%
Net margin 3-year median: -18.3%
-40.2%
ROIC 
-13.7%
ROIC, 5-year average 
-6.4%
ROE 
-57.1%

Growth

Revenue, yearly change 
-28.8%
EPS, yearly change 
–
FCF, yearly change 
+338.0%
Revenue, average a year 
-13.7%
EPS, average a year 
-30.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$176M
Total debt 
$514M
Of which operating leases 
$6.0M
Net debt 
$332M
Net debt / EBITDA 
–
Interest cover 
-4.0x
Current ratio 
4.58

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
8.31%
Total returned 
8.31%
Shares, yearly change 
-4.7%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

13.5%

Above 77% of the 285 companies in its industry, and 72% of all.

Net margin

7.1%

Above 70% of the 302 companies in its industry, and 58% of all.

ROE

10.1%

Above 68% of the 267 companies in its industry, and 60% of all.

ROA

4.0%

Above 69% of the 313 companies in its industry, and 67% of all.

Revenue growth

-28.8%

Above 7% of the 292 companies in its industry, and 3% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

Contracts with the US government

What the federal government committed in contracts to the company and its subsidiaries, by federal fiscal year (October to September).

$302M Fiscal year 2025

In federal fiscal year 2025 (October 2024 to September 2025) the US government committed $302M in contracts to the company and its subsidiaries. The year before it was $458M. That is about 41% of its revenue in the fiscal year to December 31, 2025 ($743M), though an amount committed is not revenue.

Fiscal year 2022Oct 2021 to Sep 2022

Fiscal year 2023Oct 2022 to Sep 2023

$378M

Fiscal year 2024Oct 2023 to Sep 2024

$458M

Fiscal year 2025Oct 2024 to Sep 2025

$302M

Fiscal year 2026Oct 2025 to Sep 2026

$219M

From USAspending.gov, the federal government's public spending records, as of November 1, 2026. An amount committed is not revenue of the same year: a contract running several years counts when it is signed, and the company is paid as it does the work. The company is matched through the parent company the government records it under, which adds up its subsidiaries. A subsidiary recorded under another parent can be missing.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Emergent BioSolutions Inc.
CIK
1367644
Exchange
NYSE
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
51.77M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Emergent BioSolutions's filings show?

These are Emergent BioSolutions's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about EBS

Didn't find what you were looking for?

Ask us
What is EBS's market cap?

Emergent BioSolutions Inc.'s market cap is $300M, at a price of $5.79 on November 13, 2026 and 51.77M shares.

How much revenue does EBS have?

Emergent BioSolutions had revenue of $649M over the last 12 months. Over the last 5 years it changed by -13.7% a year on average.

Does EBS pay a dividend?

No. Emergent BioSolutions paid no regular dividend over the last 12 months.

Where do the figures come from?

From Emergent BioSolutions Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.